Financials Positive

2026-08-26 17:31

- Final dividend of Re. 1.00 per equity share for FY 2025-26 recommended by the Board. - Annual General Meeting (AGM) scheduled for Thursday, September 24, 2026, at 3:00 p.m. (IST). - Record Date for determining dividend entitlement is Friday, September 4, 2026.

Governance Neutral

2026-08-22 13:08

- Outcome of postal ballot for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three (3) consecutive years (May 26, 2026, to May 25, 2029). - The resolution was passed with the requisite majority, with 99.69% of the total valid votes cast in favour.

Governance Neutral

2026-08-22 13:06

- Supriya Lifescience Ltd. announced the voting results for the postal ballot conducted via remote e-voting. - The resolution for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three consecutive years (May 26, 2026, to May 25, 2029) was passed with 99.69% votes in favor.

Business Update Negative

2026-08-18 16:40

CRITICAL RED FLAG DETECTED

- Q1 FY27 Revenue ₹190Cr vs Q1 FY26 ₹145Cr (▲31% YoY) - EBITDA ₹47Cr vs ₹52Cr (▼8.1% YoY) - PAT ₹24Cr vs ₹35Cr (▼31.4% YoY) - EBITDA Margin 25% (Q1 FY27) vs 35.9% (Q1 FY26), impacted by ₹35Cr deferred sales due to water shortages and ₹8Cr higher power costs. - Company maintains FY27 revenue guidance of ₹1,000Cr and EBITDA margin guidance of 33-35%, expecting recovery in subsequent quarters. - Launched two new anesthetic liquid inhalation products in Q2 FY27; two ADHD products and contrast media expected in pipeline/H2 FY27. - Progressing on CMO/CDMO opportunities; Phase-1 of Patalganga facility CapEx is around ₹200Cr. - Acknowledged a customs issue for a specific consignment due to a "two-day technical lapse," with a general manager in judicial custody, but expects regularization. Water issue is resolved for Q2.

Business Update Neutral

2026-08-14 17:23

- Audio recording of the Earnings Call held on August 14, 2026, discussing operational and financial performance for the quarter ended June 30, 2026, is available on the company's website.

Financials Negative

2026-08-13 23:32

- Q1 FY27 Consolidated Revenue ₹189.75 Cr vs ₹145.07 Cr (▲30.8% YoY) - EBITDA ₹47.46 Cr vs ₹51.70 Cr (▼8.2% YoY) - PAT ₹24.04 Cr vs ₹34.79 Cr (▼30.9% YoY) - EBITDA Margin 25.0% vs 35.6% (▼1060 bps)

Financials Negative

2026-08-13 19:34

- Q1 FY27 Revenue from Operations ₹189.75 Cr vs ₹145.07 Cr (▲30.8% YoY) - EBITDA ₹47.46 Cr vs ₹51.70 Cr (▼8.2% YoY) - PAT ₹24.04 Cr vs ₹34.79 Cr (▼30.9% YoY) - EBITDA Margin 25.0% vs 35.6% (▼1063 bps)

Financials Negative

2026-08-13 18:50

- Q1 FY27 Standalone Revenue ₹189.75Cr vs ₹145.07Cr (▲30.79% YoY) - EBITDA ₹47.46Cr vs ₹51.70Cr (▼8.21% YoY) - PAT ₹24.04Cr vs ₹34.79Cr (▼30.89% YoY) - EBITDA Margin 25.01% vs 35.64% (▼1063bps)

Financials Negative

2026-08-13 18:40

- Q1 FY27 Standalone Revenue ₹189.75Cr vs ₹145.07Cr (▲30.79% YoY) - EBITDA ₹50.11Cr vs ₹54.38Cr (▼7.85% YoY) - PAT ₹24.04Cr vs ₹34.79Cr (▼30.90% YoY) - EBITDA Margin 26.41% vs 37.48% (▼1107bps)

Business Update Neutral

2026-08-10 21:46

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Concall Time: 11:00 A.M. IST

Governance Neutral

2026-08-06 18:26

- Board meeting scheduled for August 13, 2026. - Purpose: To consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026. - Trading window for insiders closed from July 1, 2026, until 48 hours after results declaration on August 13, 2026.

Governance Neutral

2026-07-21 16:54

- Company to seek shareholder approval via postal ballot for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and KMP for three years from May 26, 2026, to May 25, 2029. - E-voting period: July 23, 2026 (9:00 a.m. IST) to August 21, 2026 (5:00 p.m. IST).

Business Update Negative

2026-07-04 05:21

CRITICAL RED FLAG DETECTED

- Supriya Lifescience intimated about judicial proceedings against Mr. Sreekant Sreedharan, General Manager, Sales & Marketing. - He is under judicial detention until July 17, 2026, following an investigation by the Customs Department under the NDPS Act for a procedural lapse. - The company states no material impact on operations, financial position, or governance is expected.

Financials Positive

2026-06-23 17:26

- Board recommended a final dividend of Re. 1.00 (50%) per equity share for FY 2025-26, subject to shareholder approval at the AGM. - Dividends are taxable in shareholders' hands, and the company will deduct TDS. - Shareholders need to submit tax-related documents by July 15, 2026, for appropriate TDS.

Routine Neutral

2026-06-20 16:57

- Trading window closed from July 01, 2026, until 48 hours post-Q1 FY27 unaudited financial results declaration for the quarter ended June 30, 2026. - This is in compliance with SEBI Insider Trading Regulations.

Business Update Neutral

2026-06-15 12:42

- Concall Schedule - Concall Date: June 18, 2026 - Concall Time: 02:00 PM - 03:00 PM

Routine Neutral

2026-06-09 17:42

New Filing detected. See link for details.

Business Update Positive

2026-06-02 16:14

- Reiterated FY27 guidance of approximately 20% annual revenue growth and EBITDA margin of 33-35%. - On track to achieve INR 1,000 crores revenue milestone by FY27. - Lote facility received USFDA Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification, with only one minor observation. - Patalganga land clearances secured; Phase 1 groundbreaking in FY27 with planned capex of INR 200 crores for two API/intermediate and two formulation blocks. - Scheduled annual maintenance shutdown in Q2 FY27 (August) for older blocks A&D, impacting quarterly linearity of growth. - R&D investments doubled, focusing on new APIs, CMO/CDMO/CRO, and formulations R&D. - Ambernath facility expected to start revenue contribution in FY27, with EU audit scheduled for H2 FY27. Full impact expected in 3-4 years.

Routine Neutral

2026-05-30 14:41

Supriya Lifescience Ltd. submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required by Regulation 24A of SEBI (LODR) Regulations, 2015. The report, issued by M/s. DSM & Associates, confirmed that the company fully complied with all applicable SEBI regulations and Secretarial Standards, with no non-compliances or deviations observed during the review period.

Business Update Neutral

2026-05-28 16:07

Supriya Lifescience Limited announced that the audio recording of its Earnings Call, held on May 28, 2026, discussing the operational and financial performance for the quarter and year ended March 31, 2026, is now available on the company's website.

Financials Positive

2026-05-28 09:15

Supriya Lifescience Limited reported Q4 FY26 consolidated results: Revenue ₹276.53Cr vs ₹184.11Cr (▲50.20% YoY), EBITDA ₹97.62Cr vs ₹67.58Cr (▲44.45% YoY), PAT ₹74.23Cr vs ₹50.37Cr (▲47.37% YoY). EBITDA Margin was 35.3% vs 36.7% (▼140bps). The company delivered strong performance with revenue growth driven by the anesthetic segment and improved capacity utilization.

Financials Positive

2026-05-27 18:57

Supriya Lifescience Ltd. reported Standalone Revenue of ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA of ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), and PAT of ₹74.23 Cr vs ₹50.38 Cr (▲47.36% YoY) for the quarter ended March 31, 2026. EBITDA Margin was 35.30% vs 36.71% (▼141bps). The Board recommended a final dividend of ₹1.00 per equity share (50% on face value of ₹2/- each), subject to shareholder approval.

Financials Positive

2026-05-27 18:44

Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.44% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.35% YoY). EBITDA Margin 35.29% vs 36.71% (▼142 bps). The board also recommended a final dividend of Re. 1.00 per equity share for the financial year ended March 31, 2026.

Financials Positive

2026-05-27 18:35

Standalone Revenue ₹276.53 Cr vs ₹184.11 Cr (▲50.19% YoY), EBITDA ₹97.62 Cr vs ₹67.59 Cr (▲44.43% YoY), PAT ₹74.23 Cr vs ₹50.38 Cr (▲47.34% YoY). EBITDA Margin 35.29% vs 36.71% (▼142bps). The company also recommended a final dividend of Re. 1.00 per equity share.

543434

Supriya Lifescience Ltd

Price Chart

Filing History

Unlock Full History